Laurent Chardonnet - 23 May 2023 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Reporting relationship: Chief Financial Officer
Issuer ticker: PRLD
Reported as of: 23 May 2023
Net transaction value: +$27,500
SEC form: 4
Accepted by SEC: 25 May 2023, 16:05:57 UTC
Prior SEC filing: 09 Feb 2023
Next SEC filing: 04 Mar 2024
Source filing: View source filing
Reporting owner signature: /s/ Bryant D. Lim, as Attorney-in-Fact

Key filing fact

Laurent Chardonnet filed Form 4 for Prelude Therapeutics Inc (PRLD) on 25 May 2023.

Key facts

This page summarizes Laurent Chardonnet's Form 4 filing for Prelude Therapeutics Inc (PRLD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 25 May 2023, 16:05.

Change

Previous filing in this sequence was filed on 09 Feb 2023.
Current net transaction value: +$27,500.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PRLD transaction

Common Stock

Purchase

Transaction value: $27,500
Shares: +5,000
Change %: +13%
Price: $5.50
Shares after: 42,165
Date: 23 May 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The reported total includes 1,292 shares of common stock the reporting person has acquired since the date of his last ownership report through the issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c).